CN111867676A - Portable therapeutic apparatus for treating alzheimer's disease by using light to stimulate visual nerves - Google Patents
Portable therapeutic apparatus for treating alzheimer's disease by using light to stimulate visual nerves Download PDFInfo
- Publication number
- CN111867676A CN111867676A CN201880006540.7A CN201880006540A CN111867676A CN 111867676 A CN111867676 A CN 111867676A CN 201880006540 A CN201880006540 A CN 201880006540A CN 111867676 A CN111867676 A CN 111867676A
- Authority
- CN
- China
- Prior art keywords
- light
- disease
- therapeutic apparatus
- light source
- portable therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/04—Eye-masks ; Devices to be worn on the face, not intended for looking through; Eye-pads for sunbathing
- A61F9/045—Eye-shades or visors; Shields beside, between or below the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
- A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
- A61N2005/0648—Applicators worn by the patient the applicator adapted to be worn on the head the light being directed to the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
Abstract
The present invention is a portable therapeutic device for stimulating the optic nerve with light. The LED light stimulates eyes of a subject to achieve the effect of treating, improving and preventing the Alzheimer disease. This portable therapeutic instrument includes: an eye patch which can be fixed on the face of a person and covers the eyes; a light source fixed to the eye mask; a power supply for energizing the light emitting source. The portable therapeutic apparatus has the characteristics of simple operation, convenient application and high cost performance. The portable therapeutic apparatus is not only suitable for all levels of medical institutions, but also suitable for various rehabilitation institutions, old health management institutions and various families. The portable therapeutic apparatus can be used in fixed places and the like, can be carried about as wearable equipment, and is not limited by places and time.
Description
The invention relates to the fields of neurobiology, biochemistry, physiology, senile degenerative disease treatment instruments and the like.
Alzheimer's Disease (AD), also known as senile dementia, is a degenerative disease of the central nervous system, which has an insidious onset, slow and continuous course of disease, is difficult to be found in early stage, and is one of the most common types of senile dementia. The clinical manifestations of AD are progressive mental state decay, including neuropsychiatric symptoms such as progressive memory impairment, cognitive dysfunction, personality changes, language disorders, etc., and behavior disorders and even confusion. AD has a serious impact on people's social, occupational and life functions [1 ].
The initial age of onset of AD is mostly 50 years old, and the incidence of AD increases with age, with prevalence above 65 years of about 5%, 20% above 85 years of age, and 3 times as high for women as for men. AD patients typically die from secondary infection and systemic failure within 5-6 years after the onset of disease. In 2011, a survey published by Harvard school of Public Health (Harvard school Public Health) showed that AD is second only to cancer in the major urban population in europe and america [2 ]. By 2050, the worldwide population of AD patients is expected to increase from today's 0.44 to 1.355 billion. Increasing AD will lead to significant economic and social costs [3 ]. Treatment of alzheimer's disease costs nearly $ 2,260 billion in the united states alone. Therefore, new preventive, diagnostic and therapeutic means are urgently needed.
The etiology and pathogenesis of AD have not been elucidated. The widely accepted theories are the plaque deposits formed by the accumulation of amyloid-A beta on the outer surface of brain nerve cells [4], the neurofibrillary tangles in nerve cells formed by hyperphosphorylation of tau protein [5], and neuronal loss with glial cell proliferation. Neurofibrillary tangles are found in the cytoplasm of neurons, and develop to such an extent that neurons can be denatured and destroyed, leaving behind silvery helical plaques, with an amyloid core in the middle, i.e., senile plaques. The mechanism of amyloid-A β accumulation is most prevalent in the plaque deposits in the cerebral cortex and hippocampus, also found in the striatum, amygdala and thalamus. Locally, a β -amyloid plaque deposits are the product of the development of neurofibrillary tangles to a late stage. In addition, there are neuronal loss, cortical purpurine accumulation and astrocytosis in the brains of AD patients.
Because the etiology and pathogenesis of AD are unknown, no specific treatment is available at present. Common methods include drug treatment to improve cognitive function and memory disorders; symptomatic treatment improves mental symptoms; good nursing and disease progress delaying. Drugs and rehabilitation aim to improve cognitive and memory functions, maintain the independent living ability of patients, improve quality of life [6 ]. However, these treatments are of little benefit and there are no effective drugs or methods aimed at dissolving and reducing a β -amyloid plaque deposits, in particular. Studies have shown that the therapeutic effect against AD is very limited if plaques of A β -amyloid deposits are clearly formed [6 ]. To date, alzheimer's disease is a dilemma of being non-preventive, non-early detectable and non-treatable.
The response of the brain to light stimuli has been known for a long time [7], but the effects of light stimuli on the brain of alzheimer's patients have only gained attention in recent years [8 ].
Icaccarino et al reported a study result [9]. AD model mice (5 XFAD) were placed in a black box and stimulated with LED light for one hour: AD mice were then tested for a β -soluble protein and a β -amyloid plaque deposits in the visual cortex. Six different stimulation methods were selected: 20 hertz, 40 hertz, 80 hertz, random, sustained, and no light. The detection result shows that the AD mice stimulated by the LED flickering light regulated and controlled by 40 Hz are obviously different. Soluble A in the visual cortex of AD mice1-40And soluble A1-42The expression amount is reduced by 57.96% and 57.97%, respectively. The same experiment was also confirmed in another AD model mouse (APP/PS 1) experiment. Immunohistochemical results also showed that microglial fineness of the visual cortex of 5XFAD miceThe number of cells did not change, but the diameter of microglia increased 65.8%. While the soluble A of the mice was not altered by the five other stimulation methods1-40And soluble A1-42The expression level.
In a further long-term stimulation experiment, i.e. 40 hz flashing light stimulated mice, one hour per day, with 7 consecutive days of stimulation, the results also showed a 67.2% reduction in the number of a deposited plaques on the visual cortex and a 63.7% reduction in the area of a deposited plaques compared to the control (no light stimulation) in 5XFAD mice. This suggests that light stimulation of the eyes by LEDs can improve the disease state in AD mice. The same principle can be used to treat the disease state of AD patients by stimulating human eyes with light. Therefore, the invention provides a portable therapeutic apparatus for treating, improving and preventing Alzheimer disease by stimulating eyes with LED light.
Reference to the literature
[1]Siarkosa, K.T. et al. A Review of Pharmacological Treatments for Depression in Alzheimer’s Disease. J. Alzheimer’sDisease 48, 15–34 (2015)
[2]Beydoun, M.A. et al. Nationwide Inpatient Prevalence, Predictors, and Outcomes ofAlzheimer's Disease among Older Adults in the United States, 2002-2012. JAlzheimers Dis. 48(2):361-375 (2015)
[3]Gauthier, S.et al. Current and future management of Alzheimer's disease. Alzheimers Dement.4(1):S48-50 (2008)
[4a]Oakley, H.et al. Intraneuronal β-amyloidaggregates, neurodegeneration, and neuron loss in transgenic mice with fivefamilial Alzheimer’s diseasemutations: potential factors in amyloid plaque formation. J. Neurosci. 26,10129–10140 (2006)
[4b]Bero, A. W.et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nature Neurosci. 14, 750–756 (2011)
[4c]Butterfield, D. A. et al. Evidence of oxidative damage in Alzheimer’s disease brain:central role for amyloid β β-peptide. Trends in Mol. Med.7(12):549-554, 2001.
[5a]Mattsson,N. et al. Plasma tau in Alzheimer disease. Neurology. 87(17):1827-1835 (2016)
[5b]Gratuze, M.et al. Tau hyperphosphorylation in the brain of ob/ob mice is due tohypothermia: Importance of thermoregulation in linking diabetes and Alzheimer'sdisease. Neurobiol Dis. 98:1-8 (2017)
[5c]Gratuze, M.et al. High-fat, high-sugar, and high-cholesterol consumption does not impacttau pathogenesis in a mouse model of Alzheimer's disease-like taupathology.Neurobiol Aging. 47:71-73 (2016)
[6a]Klimova, B.et al. Alzheimer's Disease and Chinese Medicine as a Useful AlternativeIntervention Tool: A Mini-ReviewAlzheimer's Disease and Chinese Medicine. CurrAlzheimer Res. (2017) Jan 16.
[6b]Liao, X. etal. Repetitive Transcranial Magnetic Stimulation as an Alternative Therapy forCognitive Impairment in Alzheimer's Disease: A Meta-Analysis. J AlzheimersDis. 48(2):463-472 (2015)
[6c]Gauthier,S. et al. Effects of the Acetylcholine Release Agent ST101 with Donepezil inAlzheimer's Disease: A Randomized Phase 2 Study. J Alzheimers Dis.48(2):473-481 (2015)
[6d]Siarkos, K.T. et al. A Review of Pharmacological Treatments for Depression in Alzheimer'sDisease. J Alzheimers Dis. 48(1):15-34 (2015)
[6e]Ashford, J.W. et al. A Role for Complementary and Integrative Medicine in Alzheimer'sDisease Prevention. J Alzheimers Dis. 48(1):13-14 (2015)
[7a]Gray, C.M., König, P., Engel, A. K.&Singer, W. Oscillatory responses in catvisual cortex exhibit inter-columnar synchronization which reflects globalstimulus properties. Nature 338, 334–337(1989).
[7b]Eckhorn, R.et al. Coherent oscillations: a mechanism of feature linking in the visualcortex Multiple electrode and correlation analyses in the cat. Biol. Cybern.60, 121–130 (1988).
[8a]Cardin, J.A. et al. Driving fast-spiking cells induces gamma rhythm and controls sensoryresponses. Nature 459, 663–667 (2009)
[8b]Sekiguchi,H. et al. Bright light therapy for sleep disturbance in dementia is mosteffective for mild to moderateAlzheimer's type dementia: a case series.Psychogeriatrics. (2017)
[9]Hannah F.Iaccarino, Annabelle C. Singer, Anthony J. Martorell1, et al, Gamma frequencyentrainment attenuates amyloid load and modifies microglia. Nature. 540,230-235 (2016)。
Provides a portable therapeutic apparatus for treating, improving and preventing Alzheimer's disease by stimulating eyes with LED light source.
Portable therapeutic apparatus for treating alzheimer's disease by stimulating optic nerve with light, characterized in that:
the therapeutic apparatus comprises:
an eye patch which can be fixed on the face of a person and covers the eyes;
a light source fixed to the eye mask;
a power supply for providing power to the light source;
a control element for adjusting the light source variation.
The portable therapeutic apparatus for treating Alzheimer's disease by utilizing light to stimulate visual nerves is characterized in that: the eye cover is made of opaque materials.
The portable therapeutic apparatus for treating Alzheimer's disease by utilizing light to stimulate visual nerves is characterized in that: the light source is fixed on the side of the eye mask contacting the face.
Further: the light source is an annular light source array consisting of a plurality of point light sources, two annular light source arrays are arranged on the eyeshade, and when the eyeshade covers the eyes, the two annular light source arrays cover the eyes.
Further: the point light source is a light emitting diode, and the light emitting diode is round or square.
Further: the diameter of the round light emitting diode is 2-5 mm.
The portable therapeutic apparatus for treating Alzheimer's disease by utilizing light to stimulate visual nerves is characterized in that: the annular array formed by the point light sources is filled with other point light sources, the arrangement mode is 1 at the circle center and 6 between the circle center and the annular array.
The portable therapeutic apparatus for treating Alzheimer's disease by utilizing light to stimulate visual nerves is characterized in that: the light wavelength of the light source is 400-800 nm, the light brightness modulation frequency is 40 Hz, the light brightness time is 1-20 ms adjustable, and the light illumination is 20-2000 lux.
The portable therapeutic apparatus for treating Alzheimer's disease by utilizing light to stimulate visual nerves is characterized in that: the power supply is a power supply device connected to the light source through a power line.
The portable therapeutic apparatus for treating Alzheimer's disease by utilizing light to stimulate visual nerves is characterized in that: the power source is a battery secured to the eye mask.
The portable therapeutic apparatus for treating Alzheimer's disease by utilizing light to stimulate visual nerves is characterized in that: the control element is a controller fixed on the power supply device for adjusting the light brightness frequency.
The portable therapeutic apparatus for treating Alzheimer's disease by utilizing light to stimulate visual nerves is characterized in that: the control element is a controller which is fixed on the eyeshade and adjusts and controls the light brightness frequency by receiving the instruction sent by the mobile communication equipment.
The portable therapeutic apparatus for treating Alzheimer's disease by utilizing light to stimulate visual nerves is characterized in that: the annular light source array is composed of 12 point light sources.
The portable therapeutic apparatus has the characteristics of simple operation, convenient application and high cost performance. The portable therapeutic apparatus is not only suitable for all levels of medical institutions (high-end hospitals, community hospitals and village and town hospitals), but also suitable for various rehabilitation institutions, old health management institutions and various families. The portable therapeutic apparatus can be used in fixed places and the like, can be taken as a wearable therapeutic apparatus, and is not limited by places and time in use. The portable therapeutic apparatus is mainly used for treating and improving Alzheimer disease patients and preventing Alzheimer disease of middle-aged and elderly people.
FIGS. 1 and 2 are schematic views of an eye cover and the distribution of LED light sources inside the eye cover;
fig. 3 is a schematic diagram of the modulation of the light intensity of the LED light source on the eye mask. T2 is the LED light source on time.
In the figure:
1 an eye patch for covering the eyes;
2 LED light sources arranged in a ring-shaped pattern and embedded on the eye mask.
The embodiment includes the following technical features:
the therapeutic apparatus includes:
an eye patch which can be fixed on the face of a person and covers the eyes;
a light source fixed to the eye mask;
a power supply for providing power to the light source;
a control element for adjusting the light source variation.
Wherein: the eye cover is made of opaque materials. Wherein the light source is fixed on one side of the eye mask contacting with the face; the light source is an annular light source array consisting of a plurality of point light sources, two annular light source arrays are arranged on the eyeshade, and when the eyeshade covers the eyes, the two annular light source arrays cover the eyes. The light source adopts a circular light emitting diode with the diameter of 2 mm; other point light sources are filled in an annular array formed by the point light sources, the arrangement mode is 1 in the circle center and 6 between the circle center and the annular array. The light wavelength of the light source is 600 nanometers, the light brightness modulation frequency is 40 Hz, the light brightness time is 1-20 milliseconds adjustable, and the light illumination is 1500 lux.
The invention relates to a portable therapeutic apparatus for treating Alzheimer disease by stimulating optic nerves by light, which has the technical idea that the eyes of patients are stimulated by LED light to achieve the effects of treating, improving and preventing Alzheimer disease.
The concrete structure and characteristics of the invention include:
portable therapeutic apparatus for treating alzheimer's disease by stimulating optic nerve with light, characterized in that:
the therapeutic apparatus comprises:
an eye patch which can be fixed on the face of a person and covers the eyes;
a light source fixed to the eye mask;
a power supply for providing power to the light source;
and a control element for adjusting brightness variation of the light source.
The eye cover is made of opaque material, preferably black.
The light source is fixed on the side of the eye mask contacting the face.
The light source is an annular light source array consisting of a plurality of point light sources, two annular light source arrays are arranged on the eyeshade, and when the eyeshade covers the eyes, the two annular light source arrays cover the eyes. The light sources are preferably arranged in a transverse elliptical ring.
The point light source is a light emitting diode which is round or square, and for round, the preferred diameter is 2-5 mm.
The other light source arrangement mode is that other point light sources are filled in an annular array formed by the point light sources, and the preferred arrangement mode is that the circle centers are 1, and 6 are arranged between the circle center and the annular array.
The key point of the invention for achieving the treatment effect lies in the parameters of the light source, as shown in fig. 3, the parameters are as follows: the light wavelength of the light source is 400-800 nm, the light brightness modulation frequency is 40 Hz, the light brightness time is 1-20 ms adjustable, and the light illumination is 20-2000 lux. After a great deal of experiments and researches of the inventor, the light source with the parameters can effectively treat and improve the disease state of the patient.
The power supply is a power supply device connected to the light source through a power line. Or a battery secured to the eye mask.
The control element is a controller fixed on the power supply device for adjusting the light brightness frequency. Or a controller which is fixed on the eyeshade and adjusts and controls the light brightness frequency by receiving the instruction sent by the mobile communication equipment.
The annular light source array is composed of 12 point light sources, and the effect is better.
The mobile communication equipment comprises a mobile phone, a wristwatch or wearable equipment.
The using method of the invention is as follows:
the eyeshade is fixed on the face and covers the eyes by an elastic fixing band, and the elastic fixing band is adjusted to a comfortable degree. The eye shield power connecting wire is connected to the power supply, and the light flicker treatment program is started. The light brightness can be adjusted by setting the T2 time according to the personal comfort level, the setting range of the T2 time is 1-20 ms (the T1 time has been fixed to 25 ms). Clicking "start" starts the light blinking stimulus. Depending on the individual specific situation, one of the treatment regimes for light flicker stimulation may be selected: (1) 15 minutes/time, 4 times/day; (2) 30 minutes/time, 2 times/day; (3) 60 minutes/time, 1 time/day. Every seven days is a course of treatment.
Example 1:
the embodiment includes the following technical features:
the therapeutic apparatus includes:
an eye patch which can be fixed on the face of a person and covers the eyes;
a light source fixed to the eye mask;
a power supply for providing power to the light source;
a control element for adjusting the light source variation.
Wherein: the eye cover is made of opaque materials. Wherein the light source is fixed on one side of the eye mask contacting with the face; the light source is an annular light source array consisting of a plurality of point light sources, two annular light source arrays are arranged on the eyeshade, and when the eyeshade covers the eyes, the two annular light source arrays cover the eyes. The light source adopts a circular light emitting diode with the diameter of 2 mm; other point light sources are filled in an annular array formed by the point light sources, the arrangement mode is 1 in the circle center and 6 between the circle center and the annular array. The light wavelength of the light source is 600 nanometers, the light brightness modulation frequency is 40 Hz, the light brightness time is 1-20 milliseconds adjustable, and the light illumination is 1500 lux.
Example 2:
the embodiment includes the following technical features:
the therapeutic apparatus includes:
an eye patch which can be fixed on the face of a person and covers the eyes;
a light source fixed to the eye mask;
a power supply for providing power to the light source;
a control element for adjusting the light source variation.
Wherein: the eye cover is made of opaque materials. Wherein the light source is fixed on one side of the eye mask contacting with the face; the light source is an annular light source array consisting of a plurality of point light sources, two annular light source arrays are arranged on the eyeshade, and when the eyeshade covers the eyes, the two annular light source arrays cover the eyes. The light source adopts a circular light emitting diode with the diameter of 5 mm; the light wavelength of the light source is 600 nanometers, the light brightness modulation frequency is 40 Hz, the light brightness time is 1-20 milliseconds adjustable, and the light illumination is 20 lux.
Example 3:
the embodiment includes the following technical features:
the therapeutic apparatus includes:
an eye patch which can be fixed on the face of a person and covers the eyes;
a light source fixed to the eye mask;
a power supply for providing power to the light source;
a control element for adjusting the light source variation.
Wherein: the eye cover is made of opaque materials. Wherein the light source is fixed on one side of the eye mask contacting with the face; the light source is an annular light source array consisting of a plurality of point light sources, two annular light source arrays are arranged on the eyeshade, and when the eyeshade covers the eyes, the two annular light source arrays cover the eyes. The light source adopts a circular light emitting diode with the diameter of 5 mm; the light wavelength of the light source is 600 nanometers, the light brightness modulation frequency is 40 Hz, the light brightness time is 1-20 milliseconds adjustable, and the light illumination is 2000 lux.
The invention is described primarily in the foregoing. The above description of the embodiments is only intended to facilitate the understanding of the core ideas of the present invention. It should be noted that, for those skilled in the art, without departing from the inventive concept, several improvements and modifications can be made to the present invention, and these improvements and modifications are also within the scope of the present invention as defined in the appended claims.
Claims (13)
- Portable therapeutic apparatus for treating alzheimer's disease by stimulating optic nerve with light, characterized in that:the therapeutic apparatus comprises:an eye patch which can be fixed on the face of a person and covers the eyes;a light source fixed to the eye mask;a power supply for providing power to the light source;a control element for adjusting the light source variation.
- The portable therapeutic apparatus for treating alzheimer's disease using light stimulation for optic nerve according to claim 1, wherein: the eye cover is made of opaque materials.
- The portable therapeutic apparatus for treating alzheimer's disease using light stimulation for optic nerve according to claim 1, wherein: the light source is fixed on the side of the eye mask contacting the face.
- The portable therapeutic apparatus for treating alzheimer's disease using the photostimulated optic nerve according to claim 3, wherein: the light source is an annular light source array consisting of a plurality of point light sources, two annular light source arrays are arranged on the eyeshade, and when the eyeshade covers the eyes, the two annular light source arrays cover the eyes.
- The portable therapeutic apparatus for treating alzheimer's disease using the photostimulated optic nerve according to claim 4, wherein: the point light source is a light emitting diode, and the light emitting diode is round or square.
- The portable therapeutic apparatus for treating alzheimer's disease using light stimulation for optic nerve according to claim 5, wherein: the diameter of the round light emitting diode is 2-5 mm.
- The portable therapeutic apparatus for treating alzheimer's disease using the photostimulated optic nerve according to claim 4, wherein: the annular array formed by the point light sources is filled with other point light sources, the arrangement mode is 1 at the circle center and 6 between the circle center and the annular array.
- The portable therapeutic apparatus for treating alzheimer's disease using light stimulation for optic nerve according to claim 1, wherein: the light wavelength of the light source is 400-800 nm, the light brightness modulation frequency is 40 Hz, the light brightness time is 1-20 ms adjustable, and the light illumination is 20-2000 lux.
- The portable therapeutic apparatus for treating alzheimer's disease using light stimulation for optic nerve according to claim 1, wherein: the power supply is a power supply device connected to the light source through a power line.
- The portable therapeutic apparatus for treating alzheimer's disease using light stimulation for optic nerve according to claim 1, wherein: the power source is a battery secured to the eye mask.
- The portable therapeutic apparatus for treating alzheimer's disease using photostimulated optic nerve according to claim 9, wherein: the control element is a controller fixed on the power supply device for adjusting the light brightness frequency.
- The portable therapeutic apparatus for treating alzheimer's disease using light stimulation of the optic nerve according to claim 9 or 10, wherein: the control element is a controller which is fixed on the eyeshade and adjusts and controls the light brightness frequency by receiving the instruction sent by the mobile communication equipment.
- The portable therapeutic apparatus for treating alzheimer's disease using the photostimulated optic nerve according to claim 4, wherein: the annular light source array is composed of 12 point light sources.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710188035.6A CN107019849A (en) | 2017-03-27 | 2017-03-27 | The portable therapeutic device of Alzheimer disease is treated using light stimulus optic nerve |
| PCT/CN2018/079879 WO2018177182A1 (en) | 2017-03-27 | 2018-03-21 | Portable therapeutic device for use in treating alzheimer's disease by using light stimulation of optic nerve |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111867676A true CN111867676A (en) | 2020-10-30 |
Family
ID=59525377
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710188035.6A Pending CN107019849A (en) | 2017-03-27 | 2017-03-27 | The portable therapeutic device of Alzheimer disease is treated using light stimulus optic nerve |
| CN201880006540.7A Pending CN111867676A (en) | 2017-03-27 | 2018-03-21 | Portable therapeutic apparatus for treating alzheimer's disease by using light to stimulate visual nerves |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710188035.6A Pending CN107019849A (en) | 2017-03-27 | 2017-03-27 | The portable therapeutic device of Alzheimer disease is treated using light stimulus optic nerve |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN107019849A (en) |
| WO (1) | WO2018177182A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107019849A (en) * | 2017-03-27 | 2017-08-08 | 关夫 | The portable therapeutic device of Alzheimer disease is treated using light stimulus optic nerve |
| CN108310665B (en) * | 2017-12-20 | 2020-08-11 | 贵州民族大学 | Light therapeutic instrument based on LED lamp pearl array |
| CN112041025B (en) * | 2019-06-17 | 2021-09-03 | 浙江莱恩海思医疗科技有限公司 | Light therapy device and light therapy apparatus for head irradiation and treatment method thereof |
| CN115779277B (en) * | 2022-11-03 | 2024-04-12 | 东北大学 | Infrared light nerve regulation and control method and storage medium for serious brain diseases |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN201543118U (en) * | 2009-11-25 | 2010-08-11 | 胡明云 | Health-care glasses |
| CN101869740A (en) * | 2010-06-23 | 2010-10-27 | 上海理工大学 | Hood device for treating brain central nervous system diseases |
| CN102300604A (en) * | 2008-12-30 | 2011-12-28 | 皇家飞利浦电子股份有限公司 | System and method for providing light therapy to a subject |
| KR20140090332A (en) * | 2013-01-07 | 2014-07-17 | 대한민국(전북기계공업고등학교장) | Therapy Glasses |
| CN106039578A (en) * | 2016-05-11 | 2016-10-26 | 付金龙 | Wearable treatment device and device control method |
| CN107019849A (en) * | 2017-03-27 | 2017-08-08 | 关夫 | The portable therapeutic device of Alzheimer disease is treated using light stimulus optic nerve |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN201308726Y (en) * | 2008-12-02 | 2009-09-16 | 南通同润生物科技有限公司 | Brain strengthening machine capable of activating brain by near-infrared light |
| RU2545904C2 (en) * | 2008-12-30 | 2015-04-10 | Конинклейке Филипс Электроникс Н.В. | System and method for phototherapy |
| CN203634651U (en) * | 2013-11-27 | 2014-06-11 | 杨小浩 | LED phototherapy mask |
| CN203710557U (en) * | 2014-03-09 | 2014-07-16 | 山东中医药大学 | Head massage device for rehabilitation of people with cerebrovascular disease |
| US10137311B2 (en) * | 2014-07-17 | 2018-11-27 | Troy HUDSON | Light therapy glasses and mobile application |
| CN104162233A (en) * | 2014-09-04 | 2014-11-26 | 电子科技大学 | Near-infrared light therapeutic apparatus for treating brain diseases |
| WO2016127183A1 (en) * | 2015-02-06 | 2016-08-11 | Noothera Technologies, Llc | Systems and methods for directed energy therapeutics |
| JP6714606B2 (en) * | 2015-03-20 | 2020-06-24 | ルー リム | Method, system and device for non-invasive neural stimulation of the brain |
| US11154228B2 (en) * | 2015-08-31 | 2021-10-26 | Zoll Medical Corporation | Electrode use indication |
-
2017
- 2017-03-27 CN CN201710188035.6A patent/CN107019849A/en active Pending
-
2018
- 2018-03-21 WO PCT/CN2018/079879 patent/WO2018177182A1/en active Application Filing
- 2018-03-21 CN CN201880006540.7A patent/CN111867676A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102300604A (en) * | 2008-12-30 | 2011-12-28 | 皇家飞利浦电子股份有限公司 | System and method for providing light therapy to a subject |
| CN201543118U (en) * | 2009-11-25 | 2010-08-11 | 胡明云 | Health-care glasses |
| CN101869740A (en) * | 2010-06-23 | 2010-10-27 | 上海理工大学 | Hood device for treating brain central nervous system diseases |
| KR20140090332A (en) * | 2013-01-07 | 2014-07-17 | 대한민국(전북기계공업고등학교장) | Therapy Glasses |
| CN106039578A (en) * | 2016-05-11 | 2016-10-26 | 付金龙 | Wearable treatment device and device control method |
| CN107019849A (en) * | 2017-03-27 | 2017-08-08 | 关夫 | The portable therapeutic device of Alzheimer disease is treated using light stimulus optic nerve |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018177182A1 (en) | 2018-10-04 |
| CN107019849A (en) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sabel et al. | Vision modulation, plasticity and restoration using non-invasive brain stimulation–An IFCN-sponsored review | |
| McDermott et al. | Gamma band neural stimulation in humans and the promise of a new modality to prevent and treat Alzheimer’s disease | |
| US10058704B2 (en) | Systems, devices and methods for the treatment of neurological disorders and conditions | |
| Kessler et al. | Differences in the experience of active and sham transcranial direct current stimulation | |
| CN111867676A (en) | Portable therapeutic apparatus for treating alzheimer's disease by using light to stimulate visual nerves | |
| EP2314346A1 (en) | Method and apparatus for treatment of neurodegenerative diseases including depression, mild cognitive impairment, and dementia | |
| Merabet et al. | Suppression of complex visual hallucinatory experiences by occipital transcranial magnetic stimulation: a case report | |
| Lappin et al. | Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial. | |
| Fregni et al. | Antiepileptic effects of repetitive transcranial magnetic stimulation in patients with cortical malformations: an EEG and clinical study | |
| US20080103548A1 (en) | Methods for treating neurological disorders, including neuropsychiatric and neuropsychological disorders, and associated systems | |
| KR20140037803A (en) | Device, system and methods for the treatment of medical disorders | |
| US20090005837A1 (en) | Method and apparatus for stimulating the neurochemistry of the brain resulting in increased overall brain function, cognitive performance, and intelligence quota | |
| Danilov et al. | Emerging noninvasive neurostimulation technologies: CN-NINM and SYMPATOCORECTION | |
| Haberbosch et al. | Safety aspects, tolerability and modeling of retinofugal alternating current stimulation | |
| KR101885678B1 (en) | Light irradiation device for inhibiting the accumulation of amyloid beta plaque | |
| Chen et al. | Transcranial electrostimulation with special waveforms enhances upper-limb motor function in patients with chronic stroke: a pilot randomized controlled trial | |
| Kirsch et al. | Cranial electrotherapy stimulation for anxiety, depression, insomnia, cognitive dysfunction, and pain | |
| JP2018166568A (en) | Gamma wave induction device and gamma wave induction method | |
| Nitsche et al. | Transcranial direct current stimulation-an adjuvant tool for the treatment of neuropsychiatric diseases? | |
| Prada et al. | Treatment of the neglect syndrome in stroke patients using a contingency electrical stimulator | |
| KR20210060117A (en) | Photic modulation headset for Alzheimer's disease | |
| Kumru et al. | Brainstem reflex excitability after high-frequency repetitive transcranial magnetic stimulation in healthy and spinal cord injury subjects | |
| Mindes et al. | Cranial electrical stimulation | |
| Huang | The modulation of cortical motor circuits and spinal reflexes using theta burst stimulation in healthy and dystonic subjects | |
| Sorokina et al. | Neurobiological mechanisms of transcranial magnetic stimulation and its comparative efficacy in tension headache and migraine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201030 |
|
| RJ01 | Rejection of invention patent application after publication |